Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Positive Data on Merck’s Keytruda Drug for Lung Cancer Presented at ESMO 2016

By Bevin Fletcher - Associate Editor, Bioscience Technology | October 12, 2016

Two new studies demonstrating the potential of Merck’s Keytruda (pembrolizumab) as a first-line treatment for metastatic non-small cell lung cancer will be presented at the European Society for Medical Oncology (ESMO) 2016 in Denmark.

The injectable drug is a humanized monoclonal antibody that amps up the body’s immune system so that it can detect and fight tumor cells by blocking a protein called PD-1.

The first study, known as KEYNOTE-024, evaluated 305 patients who were previously untreated and whose tumors expressed high levels of PD-L1. The findings were published in The New England Journal of Medicine.

READ MORE: BMS Announces Mixed Data for Opdivo at ESMO 2016

About half of participants were randomly assigned to receive a 200 mg dose of Keytruda every three weeks, while the other half received four to six cycles of chemotherapy. Those taking the immuno-oncology medicine saw a 50 percent reduction in the risk of disease progression or death and a 40 percent reduction in risk of death compared to platinum-based chemotherapy regimens, the current standard of care, according to the company.

Two of the most common side effects were diarrhea, and fatigue. According to the release there was one treatment related death in a patient receiving Keytruda, but the cause was unknown.

“These data from KEYNOTE-024 demonstrate the potential of Keytruda to change the way non-small cell lung cancer is currently treated,” lead author Dr. Martin Reck, head of the thoracic oncology department at the LugenClinic in Germany said in a statement. “This provides additional evidence that testing for PD-L1 levels should become standard in lung cancer at first diagnosis to guide treatment decisions.”

The second study, known as KEYNOTE-021, was published in The Lancet Oncology, and enrolled 123 patients regardless of PD-L1 expression of their tumors.  Findings show that Keytruda, in combination with chemotherapy, works better than chemotherapy alone, and reduced the risk of disease progression or death by 47 percent.

The U.S. Food and Drug Administration had previously granted the drug Breakthrough Therapy Designation and approved it for treatment of patients with advanced non-small cell lung cancer who had already undergone chemotherapy.

Related Articles Read More >

Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
Waters touts six-fold robustness with new Xevo TQ Absolute XR
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE